MedTrace Logo

Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19

NCT04836260 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-04-08

No results posted yet for this study

Summary

Convalescent plasma therapy has been recognized as safe and plasma transfusion is routinely used in clinical practice. A recent study showed that early administration of convalescent plasma can decrease the risk of complications in specific high-risk population.

The aim of the present study is to offer convalescent plasma therapy to immunocompromised patients and older adults in the early phase of a SARS-Cov-2 infection in order to accelerate viral clearance and prevent complication

Conditions

  • Covid19
  • Immuno-Deficiency
  • Old Age; Debility

Interventions

DRUG

SARS-CoV-2 convalescent plasma

Included patients will receive at least one unit of convalescent plasma with NTAB titer ≥1:160 at maximum 3-7 days after diagnosis by RT-PCR or symptom onset. A second unit of plasma from a different donor can be proposed 24h after the first unit if immunocompromised and/or the patient received less than 3-5ml/kg of plasma volume. Additional units can be exceptionnally infused, at the investigator discretion.

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    collaborator OTHER

  • Ospedale Regionale di Lugano

    collaborator OTHER

  • Hôpital Fribourgeois

    collaborator OTHER

  • University Hospital, Geneva

    lead OTHER

Principal Investigators

  • Laurent Kaiser, MD · University Hospital, Geneva

  • Enos Bernasconi, MD · Ospedale Regionale di Lugano

  • Véronique Erard, MD · HFR-Fribourg Hôpital Cantonal

  • Maja Weisser, MD · Klinik Infektiologie & Spitalhygiene

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-08
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04836260 on ClinicalTrials.gov